No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Express News | SiChuan and Hubei have launched a joint investigation on "returned drugs," and three pharmacies have suspended medical insurance settlements.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Mayinglong Pharmaceutical Group (600993.SH): has not yet connected to deepseek.
Gelonghui, February 24th丨Mayinglong Pharmaceutical Group (600993.SH) stated on the investor interaction platform that the company has not yet connected to deepseek.
Mayinglong Pharmaceutical Group (600993): A traditional brand of Traditional Chinese Medicine in the field of proctology, adhering to tradition and innovating for development.
With a classic heritage of over 400 years, focusing on anal and rectal medications, the development spans multiple fields. Mayinglong Pharmaceutical Group was founded in 1582 and has become a "Chinese Time-Honored Brand" with a continuous operation of 440 years. The company's main Business focuses on anal and rectal health medications.
HAITONG INT'L: Bullish on the bottom reversal of the Traditional Chinese Medicine Industry, with the State-owned Enterprise Reform and mergers and acquisitions resonating in development.
As aging continues to intensify, the demand in the Silver economy and chronic disease medication-related fields is viewed as Bullish.
Mayinglong Pharmaceutical Group's MYL Ointment Gets Regulatory Approval for Clinical Trials
